Dunn, Claire

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

Klein, C., Waldhauer, I., Nicolini, V. G., Freimoser-Grundschober, A., Nayak, T., Vugts, D. J., Dunn, C., Bolijn, M., Benz, J., Stihle, M., et al. (2017) · OncoImmunology

Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and Biomarkers

Cited by 281

Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection

Das, A., Hoare, M., Davies, N., Lopes, A. R., Dunn, C., Kennedy, P. T. F., Alexander, G., Finney, H., Lawson, A., Plunkett, F. J., et al. (2008) · The Journal of Experimental Medicine

Hepatitis B Virus StudiesT-cell and B-cell Immunology

Cited by 256

CXCR6 marks a novel subset of T-betloEomeshi natural killer cells residing in human liver

Stegmann, K. A., Robertson, F., Hansi, N., Gill, U., Pallant, C., Christophides, T., Pallett, L. J., Peppa, D., Dunn, C., Fusai, G., et al. (2016) · Scientific Reports

Immune Cell Function and InteractionLiver physiology and pathology

Cited by 235

Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial

Røssevold, A. H., Andresen, N. K., Bjerre, C. A., Gilje, B., Jakobsen, E. H., Raj, S. X., Falk, R. S., Russnes, H. G., Jahr, T., Mathiesen, R. R., et al. (2022) · Nature Medicine

Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies

Cited by 89

Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer

Jin, Y., Lorvik, K. B., Jin, Y., Beck, C., Sike, A., Persiconi, I., Kvaløy, E., Saatcioglu, F., Dunn, C., & Kyte, J. A. (2022) · Molecular Therapy - Oncolytics

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 26